# Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer

> **NCT01752517** · — · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** NI group

## Key facts

- **NCT ID:** NCT01752517
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2014-12
- **Final completion:** 2015-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2012-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01752517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01752517, "Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01752517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*